139 related articles for article (PubMed ID: 21741379)
1. A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin.
Warren CR; Catts ZA; Farach-Carson MC
Exp Cell Res; 2011 Sep; 317(15):2099-109. PubMed ID: 21741379
[TBL] [Abstract][Full Text] [Related]
2. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Jimenez-Sainz J; Jensen RB
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.
Heczkova M; Machackova E; Macinga P; Gallmeier E; Cahova M; Spicak J; Jirsa M; Foretova L; Hucl T
Cancer Biol Ther; 2019; 20(5):633-641. PubMed ID: 30638113
[TBL] [Abstract][Full Text] [Related]
4. Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant.
Li L; Biswas K; Habib LA; Kuznetsov SG; Hamel N; Kirchhoff T; Wong N; Armel S; Chong G; Narod SA; Claes K; Offit K; Robson ME; Stauffer S; Sharan SK; Foulkes WD
Hum Mutat; 2009 Nov; 30(11):1543-50. PubMed ID: 19795481
[TBL] [Abstract][Full Text] [Related]
5. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
Borg A; Haile RW; Malone KE; Capanu M; Diep A; Törngren T; Teraoka S; Begg CB; Thomas DC; Concannon P; Mellemkjaer L; Bernstein L; Tellhed L; Xue S; Olson ER; Liang X; Dolle J; Børresen-Dale AL; Bernstein JL
Hum Mutat; 2010 Mar; 31(3):E1200-40. PubMed ID: 20104584
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
[TBL] [Abstract][Full Text] [Related]
7. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
8. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
Guidugli L; Pankratz VS; Singh N; Thompson J; Erding CA; Engel C; Schmutzler R; Domchek S; Nathanson K; Radice P; Singer C; Tonin PN; Lindor NM; Goldgar DE; Couch FJ
Cancer Res; 2013 Jan; 73(1):265-75. PubMed ID: 23108138
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
[TBL] [Abstract][Full Text] [Related]
10. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
[TBL] [Abstract][Full Text] [Related]
11. The functional impact of variants of uncertain significance in BRCA2.
Mesman RLS; Calléja FMGR; Hendriks G; Morolli B; Misovic B; Devilee P; van Asperen CJ; Vrieling H; Vreeswijk MPG
Genet Med; 2019 Feb; 21(2):293-302. PubMed ID: 29988080
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
13. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
[TBL] [Abstract][Full Text] [Related]
14. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
15. The
Du ZH; Xia Y; Yang Q; Gao S
Technol Cancer Res Treat; 2020; 19():1533033820983289. PubMed ID: 33357097
[TBL] [Abstract][Full Text] [Related]
16. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
17. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
18. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
[TBL] [Abstract][Full Text] [Related]
19. An efficient pipeline for the generation and functional analysis of human BRCA2 variants of uncertain significance.
Hendriks G; Morolli B; Calléja FM; Plomp A; Mesman RL; Meijers M; Sharan SK; Vreeswijk MP; Vrieling H
Hum Mutat; 2014 Nov; 35(11):1382-91. PubMed ID: 25146914
[TBL] [Abstract][Full Text] [Related]
20. Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
Meyer S; Stevens A; Paredes R; Schneider M; Walker MJ; Williamson AJK; Gonzalez-Sanchez MB; Smetsers S; Dalal V; Teng HY; White DJ; Taylor S; Muter J; Pierce A; de Leonibus C; Rockx DAP; Rooimans MA; Spooncer E; Stauffer S; Biswas K; Godthelp B; Dorsman J; Clayton PE; Sharan SK; Whetton AD
Cell Death Dis; 2017 Jun; 8(6):e2875. PubMed ID: 28617445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
